• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    BiomX's Zorronet Puts Full AI Command-and-Control in the Palm of Your Hand

    5/6/26 4:15:00 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PHGE alert in real time by email

    NETANYA, Israel, May 06, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company") today announced that its Zorronet subsidiary has launched a secure mobile application that brings its system directly to operators in the field, available now on Google Play and the Apple App Store, and is available for all customers.

    Zorronet develops AI-powered software that connects cameras, sensors, drones, and IoT devices into a single system. Its technology is already in use in cities and regional councils and across Israel, as well as with Israel Railways, among other organizations.

    Today, control room operators deal with more data than they can realistically process. Alerts come from different systems, and information is often conveyed using messaging apps because they're fast and available. However, these tools often introduce privacy risks, cybersecurity concerns, and uncontrolled exposure of sensitive information. They weren't designed to handle multiple data sources or support structured coordination.

    Zorronet's app changes this. Instead of relying on multiple applications to coordinate information, the system does it before users even see it. Zorronet replaces fragmented workflows with a single system that determines what matters, validates it, and delivers it as structured alerts and updates. Each user sees only what is relevant to their role, while the system combines the simplicity and speed of modern communication tools with secure data control. This enables a real-time operational view that shows what is happening, where it is happening, and who is closest to respond while the system assigns responsibility and guide action in real time.

    At its core, the application runs on a mobile command-and-control system that connects existing security infrastructure with external tools, including mapping systems and cloud-based platforms. It uses proprietary analytics and AI models to classify and validate data in real time, integrating live feeds into a shared operational view. Meanwhile, the system adapts over time, incorporating user feedback and machine learning, evolving with each deployment.

    By bringing this system to mobile devices, Zorronet users have access to a professional-grade mobile-first command-and-control system within a secure and controlled app, reducing manual effort and enabling faster, more consistent outcomes.

    The global command and control systems market is projected to reach approximately $44 billion by 2030, and the global video analytics market is expected to exceed $37 billion over the same period, driven by increasing demand for integrated situational awareness and AI-enabled decision-support platforms.

    "At Zorronet, we listen to the needs of the people in the field, specifically the people on the ground and security experts," said Idan Wasserman, CEO of Zorronet. "We are proud to have successfully designed and developed an application that combines the newest worlds of security, command-and-control, AI, and operational communication with what operators on the ground are looking for. We tested the application alongside leading security professionals in real operational scenarios, and built a system that not only delivers information, but helps users understand what is happening and what to do next in real time."

    "Zorronet's system is already deployed across defense and infrastructure where real-time decision-making is critical," said Michael Oster, CEO of BiomX. "Extending this capability to mobile devices enables more responsive execution, as systems become more complex and data-intensive. This is a natural extension of Zorronet's proven software-driven capabilities that connect detection, analysis, and response into a single, unified system."

    The app is available to download on both the Google Play and Apple App Store.

    About Zorronet

    Zorronet develops AI-powered command and control software that transforms distributed surveillance systems into integrated operational intelligence networks. The company's platform connects cameras, sensors, drones, and IoT devices into a unified environment that detects, classifies, and escalates potential threats in near real time. Using artificial intelligence, machine learning, and secure communications architecture, Zorronet helps security operators analyze large volumes of sensor data and prioritize responses more effectively. The platform supports deployments ranging from individual facilities to large-scale security networks across defense, homeland security, and critical infrastructure environments.

    Forward Looking Statement

    This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended". These forward-looking statements include, but are not limited to, statements regarding BiomX's growth strategy, including statements regarding the expected capabilities, deployment, and adoption of Zorronet's mobile application, the Company's development of AI-driven command-and-control technologies and, the Company's ability to capitalize on structural constraints within the defense industrial base. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Such risks include, among others, the Company's ability to develop, integrate, and commercialize its technologies, customer adoption and deployment timing, and general market conditions. Additional risks are described in the Company's current report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on May 5, 2026, the annual report on Form 10-K filed with the SEC on February 19, 2026, as supplemented by the 10-K/A filed with the SEC on April 30, 2206 and with the other filings with the SEC, including its most recent public filings. The Company undertakes no obligation to update these statements except as required by law.

    Contact

    Yair Ohayon

    Yairo@biomx.com



    Get the next $PHGE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PHGE

    DatePrice TargetRatingAnalyst
    11/16/2021$16.00 → $13.00Buy
    Chardan Capital
    10/19/2021$28.00 → $16.00Buy
    Chardan Capital
    10/18/2021$20.00 → $10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PHGE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Another Prominent Defense Technology Leader Joins BiomX: Prof. Gabby Sarusi, Former VP and Chief Scientist at Elbit

    NETANYA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), today announced the appointment of Prof. Gabby Sarusi as Strategic Advisor to the Company. Prof. Sarusi will advise BiomX as the Company as the company expands its presence in the defense, security, critical infrastructure, and first-response sectors, and drawing on his experience spanning technology development, operational leadership, and long-term strategic planning. His advisory role is expected to support management in evaluating new opportunities and advancing the Company's long-term growth strategy. Prof. Sarusi brings a combination of scientific, defense-industry, commercial, and

    6/2/26 9:32:30 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Zorronet Brings Autonomous C5ISR to Hardened Sites Without Public Cloud Dependence

    NETANYA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), today announced the expansion of its Zorronet subsidiary's autonomous C5ISR suite to support fully secure on-premise, hybrid, and closed-loop deployments for defense, security, and critical infrastructure. The expanded offering enables organizations to run the full Zorronet C5ISR suite inside hardened sites, secured intranets, and restricted infrastructure without relying on the public cloud. The expansion reflects growing demand for autonomous command-and-control systems that can function locally inside secured infrastructure, a priority highlighted by US President Donald Trump's push to

    6/1/26 9:25:36 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Appoints IDF Colonel (res.) Roy Timor-Rousso as Chief Business Officer to Strengthen Defense & Security Operations

    NETANYA, Israel, May 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), today announced the appointment of Roy Timor-Rousso as Chief Business Officer (CBO), adding senior business & operational leadership as the Company continues building around defense, security, and first response technologies. As a Colonel (res.) in the Israel Defense Forces, Mr. Timor-Rousso's military leadership experience gives him direct understanding of operational command, field coordination, and how technology must serve soldiers and operators on the ground. Bringing on Mr. Timor-Rousso further strengthens BiomX's operating structure with leadership experience in coordinating subsid

    5/27/26 9:40:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Yeganeh Reuven

    4 - BiomX Inc. (0001739174) (Issuer)

    3/18/26 5:47:41 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Yeganeh Reuven sold $3,350,000 worth of shares (670,000 units at $5.00) and converted options into 670,000 shares (SEC Form 4)

    4 - BiomX Inc. (0001739174) (Issuer)

    3/13/26 4:30:02 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Bidas Liat Cohavi

    3 - BiomX Inc. (0001739174) (Issuer)

    3/3/26 9:27:51 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $PHGE
    SEC Filings

    View All

    Chardan Capital reiterated coverage on BiomX with a new price target

    Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $13.00 from $16.00 previously

    11/16/21 9:23:03 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chardan Capital reiterated coverage on BiomX with a new price target

    Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $16.00 from $28.00 previously

    10/19/21 8:36:54 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HC Wainwright & Co. reiterated coverage on BiomX with a new price target

    HC Wainwright & Co. reiterated coverage of BiomX with a rating of Buy and set a new price target of $10.00 from $20.00 previously

    10/18/21 12:27:44 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - BiomX Inc. (0001739174) (Filer)

    6/5/26 4:30:42 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by BiomX Inc.

    SCHEDULE 13D/A - BiomX Inc. (0001739174) (Subject)

    5/28/26 6:13:53 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - BiomX Inc. (0001739174) (Filer)

    5/28/26 8:09:55 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Leadership Updates

    Live Leadership Updates

    View All

    Another Prominent Defense Technology Leader Joins BiomX: Prof. Gabby Sarusi, Former VP and Chief Scientist at Elbit

    NETANYA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), today announced the appointment of Prof. Gabby Sarusi as Strategic Advisor to the Company. Prof. Sarusi will advise BiomX as the Company as the company expands its presence in the defense, security, critical infrastructure, and first-response sectors, and drawing on his experience spanning technology development, operational leadership, and long-term strategic planning. His advisory role is expected to support management in evaluating new opportunities and advancing the Company's long-term growth strategy. Prof. Sarusi brings a combination of scientific, defense-industry, commercial, and

    6/2/26 9:32:30 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Appoints IDF Colonel (res.) Roy Timor-Rousso as Chief Business Officer to Strengthen Defense & Security Operations

    NETANYA, Israel, May 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), today announced the appointment of Roy Timor-Rousso as Chief Business Officer (CBO), adding senior business & operational leadership as the Company continues building around defense, security, and first response technologies. As a Colonel (res.) in the Israel Defense Forces, Mr. Timor-Rousso's military leadership experience gives him direct understanding of operational command, field coordination, and how technology must serve soldiers and operators on the ground. Bringing on Mr. Timor-Rousso further strengthens BiomX's operating structure with leadership experience in coordinating subsid

    5/27/26 9:40:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Adds Former Mossad Deputy to Advisory Board

    NETANYA, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE), today announced the appointment of Dr. Ehud (Udi) Levi to its newly formed Advisory Board.  Dr. Levi will support the Company in evaluating and pursuing strategic alternatives and business opportunities, with an emphasis on security and defense, aerial response systems, and counter-UAS (C-UAS) technologies. This will include identifying and assessing potential partnerships, transactions, and new business directions aligned with the Company's expansion into security and defense applications. Dr. Levi brings more than three decades of experience in Israeli intelligence and national security. He served in Unit 8200

    3/30/26 9:28:34 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Financials

    Live finance-specific insights

    View All

    BiomX Acquires Zorronet, Autonomous AI Command-and-Control Platform for Real-Time Defense and Security Applications

    NETANYA, Israel and REHOVOT, Israel, April 10, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) (the "Company") today announced that it has completed the acquisition of 100% of Zorronet from Water.io (TASE: WATR). This acquisition marks BiomX's entry into the defense, security and rescue sector and establishes a foundation for building a diversified portfolio of defense, rescue, and security capabilities aligned with growing global demand. The acquisition was completed pursuant to a definitive agreement with Water.io. Zorronet is a developer of AI-powered command-and-control software that uses artificial intelligence and machine learning to integrate video analytics, drones, sensors, and I

    4/10/26 8:30:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Announces $3.0 Million Private Placement

    NESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has entered into definitive agreements in connection with a private investment in public equity ("Private Placement") financing for expected gross proceeds of approximately $3.0 million, before deducting placement agent fees and other offering expenses. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. About the Private PlacementIn the Private Placement, the Company agreed to issue and sell shares of its Se

    12/29/25 8:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates

    Positive FDA feedback confirms clear clinical pathway for BX011 targeting S. aureus in Diabetic Foot Infections, building on Company's prior Phase 2 success  BiomX expects FDA feedback on BX004 clinical hold imminently; Enrollment and dosing of patients outside the U.S. are continuing in accordance with protocol Positive FDA feedback received in October provided guidance for potential Phase 3 development pathways of BX004 BiomX will host a conference call and webcast today at 8:30 AM ET NESS ZIONA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specif

    11/12/25 7:30:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BiomX Inc.

    SC 13G/A - BiomX Inc. (0001739174) (Subject)

    11/13/24 5:14:46 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by BiomX Inc.

    SC 13G/A - BiomX Inc. (0001739174) (Subject)

    11/4/24 4:05:35 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by BiomX Inc.

    SC 13G/A - BiomX Inc. (0001739174) (Subject)

    10/28/24 4:01:32 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care